Skip to main navigation

Terms and Conditions

*

Client nav

About Arcturus

RNA Medicines

Technologies

Pipeline

Business Development

Publications

Investor Relations

Media Coverage

Categories

Year

CEO Media Group “A new kind of vaccine: Interview with Arcturus Therapeutics’ P…

September 12, 2023

CEO Media Group “Arcturus Therapeutics - A New Kind of Vaccine”

August 29, 2023

Fierce Pharma “Arcturus JV scored $115M in Japanese grants to boost mRNA manufa…

August 14, 2023

Source

Fierce Pharma

Endpoints News “Arcturus Therapeutics handed $115M from Japanese government to …

August 14, 2023

Source

Endpoints News

Nature “The next generation of coronavirus vaccines: a graphical guide”

February 1, 2023

Nature Reviews Drug Discovery “mRNA pioneers refocus on therapeutics”

September 15, 2022

Endpoints News “Arcturus touts $63M BARDA award for new mRNA influenza vaccine…

September 1, 2022

The Wall Street Journal “Arcturus Receives BARDA Award to Support Development o…

August 31, 2022

QPS “The Potential of a Self-Amplifying mRNA Vaccine Is Heard Loud and Clear”

June 13, 2022

Arcturus Therapeutics, a U.S. developer of mRNA medicines, has established a Ja…

June 9, 2022

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 105

Arcturus-Covid19 Message.jpg

Nasdaq combined

Investor Home

Corporate Governance

Governance Highlights
Management Team
Board of Directors
Committee Composition

Financials & Filings

SEC Filings
Annual Reports
Quarterly Results

News & Events

Press Releases
Videos
Media Coverage
Presentations
Events

Stock Information

Stock Quote
Historical Price Lookup
Analyst Coverage

Investor Resources

Investor FAQ
Contact IR
Email Alerts

Home
Contact
Careers
Terms and Conditions
Privacy Policy

© 2024 Arcturus Therapeutics, Inc.

Search